1 Introduction
2 MicroRNA
Breast cancer subtype | Molecular subtypes | Subtype-specific circulating miRNA | Ref | ||
---|---|---|---|---|---|
ER | PR | HER2 | |||
Luminal A | + | + | − | miR-29a, miR-181a, miR-652 | [24] |
Luminal B | + | + | + | miR-342 | [25] |
HER2 + ve | + | − | + | miR-10b, miR-21 | [26] |
Basal (TNBC) | − | − | − | miR-210 | [27] |
2.1 miRNA biogenesis and action
2.2 Breast cancer diagnosis
2.3 miRNA in metastatic breast cancer tissue
2.4 Metastases
Metastasis sites | Breast cancer subtype | |||
---|---|---|---|---|
Luminal A | Luminal B | HER2 + ve | Basal | |
Brain | 6.6 % | 8.2 % | 23.3 % | 18.1 % |
Lungs | 25.1 % | 29.2 % | 32.4 % | 35.4 % |
Bone | 62.1 % | 64.5 % | 47.7 % | 32.2 % |
Liver | 25.1 % | 26 % | 39.9 % | 23.8 % |
2.5 Subtype and metastasis stage
Breast cancer subtype | % Metastasis at presentation | % Metastasis at recurrence | MBC median survival (years) |
---|---|---|---|
Luminal A | 2–2.6 | 27.8 | 2.2 |
Luminal B | 1–2.5 | 42.9 | 1.6 |
HER2 | 5–6 | 51.4 | 1.3 |
Basal | 4–5 | 35.1 | 0.7 |
2.6 Breast cancer treatments
2.7 Chemotherapy and miRNA
Subtype | Circulating miRNA | Menopause | Node negative | Node positive |
---|---|---|---|---|
Luminal A | miR-19a, miR-205 | Pre | Tamoxifen ± chemotherapy | Chemotherapy + tamoxifen ± ovarian ablation |
Post | Aromatase inhibitor (AI) + tamoxifen ± chemotherapy | Chemotherapy + AI with tamoxifen | ||
Luminal B | N.D | Pre | Tamoxifen + Herceptin ± chemotherapy | Chemotherapy + Herceptin + tamoxifen |
Post | AI with tamoxifen + herceptin ± chemotherapy | Chemotherapy + herceptin + AI with tamoxifen | ||
HER2 | miR-210 | Pre | Herceptin + chemotherapy | Herceptin + chemotherapy |
Post | Herceptin + chemotherapy | Herceptin + chemotherapy | ||
Basal | miR-27a, miR-30e, miR-155, miR-493 | Pre | ±Chemotherapy | Chemotherapy |
Post | ±Chemotherapy | Chemotherapy |
3 Diagnosing metastatic disease
3.1 Circulating miRNA as biomarkers in metastatic breast cancer
MicroRNA | Tumour | Ref. | Cohort (N) |
---|---|---|---|
miRNA-105 | Breast (serum) | [102] | 38 Patients |
miRNA-21 | Breast (serum) | [103] | 102 Patients, 20 controls |
miRNA-141, miRNA-200a, miRNA-200b, miRNA-200c, miRNA-203, miRNA-210, miRNA-375, miRNA-801 | Breast (serum) | [104] | 61 Patients, 76 controls |
miRNA-215, miRNA-299-5p, miRNA-411, miRNA-452 | Breast (serum) | [105] | 75 Patients, 20 controls |
miRNA-20a, miRNA-214 | Breast (serum) | [106] | 48 Patients, 54 controls |
miRNA-210 | Breast (serum) | [94] | 8 Patients, 31 controls |
miRNA-17, miRNA-155 | Breast (serum) | [107] | 72 Patients, 40 controls |
miRNA-10b, miRNA-373 | Breast (serum) | [108] | 35 Patients, 10 controls |
miRNA-10b, miRNA-34a, miRNA-155 | Breast (serum) | [7] | 30 Patients, 29 controls |
miRNA-10b | Breast (serum) | [109] | 20 Patients, 10 controls |
miRNA-10b | Breast (serum) | [110] | 122 Patients, 59 controls |
miRNA-10b | Breast (serum) | [111] | 23 Patients |
miRNA-126, miRNA-335 | Breast (tissue) | [48] | 11 Patients |
miRNA-21, miRNA-139-5p, miRNA-486-5p | Breast (tissue) | [9] | 6 Patients |
Let 7i, miRNA-16, miRNA-26a, miRNA-27a, miRNA-143, miRNA-196a, miRNA-375, miRNA-503, miRNA-519a, miRNA-519b-3q, miRNA-361-5p | Breast (tissue) | [10] | 48 Patients |
miRNA-27b-3q, miRNA-107, miRNA-103a-3p | Breast (tissue) | [11] | 58 Patients |
miRNA-22 | Breast (tissue) | [112] | 108 Patients |
miRNA-373 | Breast (tissue) | [113] | 11 Patients |
miRNA-21 | Breast (tissue) | [114] | 113 Patients |
miRNA-15a, miRNA-103, miRNA-148a, miRNA-320a, miRNA-451, miRNA-596 | Colon (serum) | [115] | 30 Patients |
miRNA-27b, miRNA-158a, miRNA-326 | Colon (serum) | [116] | 150 Patients |
miRNA-29a | Colon (serum) | [117] | 20 Patients |
miRNA-200c | Colon (serum) | [118] | 182 Patients |
miRNA-141 | Prostate (serum) | [119] | 21 Patients |
miRNA-141 | Prostate (serum) | [120] | 56 Patients |
miRNA-141, miRNA-375, miRNA-378 | Prostate (serum) | [121] | 84 Patients |
miRNA-20a, miRNA-203 | Cervical (serum) | [122] | 80 Patients |
miRNA-21, miRNA-27a, miRNA-106b, miRNA-146a, miRNA-148a, miRNA-223 | Gastric (serum) | [123] | 20 Controls, 16 patients |